State Street Corp Purchases 16,188 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

State Street Corp raised its position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 1.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 973,908 shares of the biotechnology company’s stock after acquiring an additional 16,188 shares during the quarter. State Street Corp owned approximately 1.64% of Aldeyra Therapeutics worth $5,249,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Jacobs Levy Equity Management Inc. increased its stake in shares of Aldeyra Therapeutics by 163.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock valued at $2,571,000 after buying an additional 295,864 shares during the period. Paloma Partners Management Co bought a new position in Aldeyra Therapeutics in the 3rd quarter worth $62,000. PDT Partners LLC purchased a new stake in shares of Aldeyra Therapeutics in the 3rd quarter worth about $169,000. Captrust Financial Advisors lifted its position in shares of Aldeyra Therapeutics by 89.3% in the 3rd quarter. Captrust Financial Advisors now owns 19,261 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 9,087 shares during the period. Finally, BNP Paribas Financial Markets increased its position in shares of Aldeyra Therapeutics by 253.3% during the third quarter. BNP Paribas Financial Markets now owns 14,229 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 10,201 shares during the period. 59.71% of the stock is owned by institutional investors.

Aldeyra Therapeutics Price Performance

Shares of ALDX opened at $4.94 on Monday. The company has a 50-day simple moving average of $5.06 and a two-hundred day simple moving average of $4.81. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80. Aldeyra Therapeutics, Inc has a one year low of $2.71 and a one year high of $6.55.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) EPS for the quarter, meeting analysts’ consensus estimates of ($0.25). Research analysts anticipate that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current fiscal year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.